Edition:
United Kingdom

People: PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

38.00USD
19 Oct 2018
Change (% chg)

$-1.30 (-3.31%)
Prev Close
$39.30
Open
$39.39
Day's High
$39.90
Day's Low
$37.89
Volume
204,918
Avg. Vol
381,419
52-wk High
$52.95
52-wk Low
$14.88

Almstead, Neil 

Dr. Neil Almstead Ph.D. is Executive Vice President, Research, Pharmaceutical Operations & Technology of PTC Therapeutics Inc. Dr. Almstead has been employed with PTC since 2000. He served as our Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter & Gamble Company, a publicly traded consumer products company. Dr. Almstead has co-authored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders, oncology and inflammatory diseases. Dr. Almstead received a B.S. from Clarkson University and a Ph.D. in Organic Chemistry from the University of Illinois at Urbana-Champaign.

Basic Compensation

Total Annual Compensation, USD 600,257
Restricted Stock Award, USD 67,380
Long-Term Incentive Plans, USD --
All Other, USD 284,281
Fiscal Year Total, USD 951,918

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Schmertzler

242,177

Stuart Peltz

2,172,680

Christine Utter

870,741

Marcio Souza

1,524,270

Neil Almstead

951,918

Mark Boulding

1,121,910
As Of  31 Dec 2017